Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


David Wild


Toronto, Canada
David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.

Latest From David Wild

Gene Therapy’s Next Target: Our Microbes

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Innovation Gene Therapy

Once Destined For Pro Rodeo, Women’s Health CEO Rides A Different Horse

2024 In Vivo Rising Leader Somer Baburek wants to overhaul how endometriosis is diagnosed and managed with a product that she says has billion-dollar potential.

Rising Leaders Women's Health

Jazz’s CNS Pipeline Demonstrates Transformation

With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.

Market Intelligence Neurology

Will AI Obviate The Need For Animal Trials?

Quris-AI has built a platform that can simulate genetically diverse clinical trials on a chip. The technology may reduce biopharma’s need for animal testing and de-risk human testing. 

Innovation Artificial Intelligence

Japan’s Biotech Ecosystem Could Be Headed For An Upswing

After decades of lackluster start-up innovation despite award-winning science, Japan’s government and big pharma players are taking steps to spur biotech growth. 

Market Intelligence Research & Development

The Truly Transformational Potential Of AI Relies On The Data

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.

Commercial Strategies Artificial Intelligence
See All